Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
International Immunopharmacology|December 29, 2023
A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatoryHui Zhang, Ke Hu, Yumeng Lu, et al.Archives of Biochemistry and Biophysics|September 30, 2023
Molecular mechanism by which RRM2-inhibitor (cholagogue osalmid) plus bafilomycin A1 cause autophagic cell death in multiple myelomaShushan Guo, Zhijian Xu, Qilin Feng, et al.International Immunopharmacology|November 1, 2023
Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cellsQilin Feng, Ke Hu, Huifang Hu, et al.Cancer Letters|March 13, 2020
A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomibGege Chen, Ke Hu, Haiguo Sun, et al.Signal Transduction and Targeted Therapy|April 17, 2020
A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathwayKang Lu, Bo Li, Hui Zhang, et al.Archives of Biochemistry and Biophysics|February 17, 2024
Dihydrocelastrol induces cell death and suppresses angiogenesis through BCR/AP-1/junb signalling in diffuse large B cell lymphomaYue Lai, Shushan Guo, Qiongwei Tang, et al.Journal of Experimental & Clinical Cancer Research : CR|June 11, 2020
A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastropheLiangning Hu, Bo Li, Gege Chen, et al.Acta Biochimica Et Biophysica Sinica|March 25, 2017
Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivoLiangning Hu, Huiqun Wu, Bo Li, et al.Journal of Biomedical Science|May 13, 2022
Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myelomaYongsheng Xie, Yingcong Wang, Zhijian Xu, et al.Acta Biochimica Et Biophysica Sinica|November 27, 2023
Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulationShuhan Jin, Bo Li, Bibo Zhang, et al.Pageof 5